Dai Xuyang, He Linfeng, Hu Naihua, Guo Chaocheng, Zhou Mengting, Zhao Xingtao, Wang Cheng, Gong Lihong, Ma Cheng, Xue Xinyan, Li Yunxia
School of Pharmacy, Key Laboratory of Standardization for Chinese Herbal Medicine, Ministry of Education, National Key Laboratory Breeding Base of Systematic Research, Development and Utilization of Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Front Pharmacol. 2021 Nov 15;12:734670. doi: 10.3389/fphar.2021.734670. eCollection 2021.
In the prescription of Traditional Chinese Medicine for lipid metabolism, (ZhiHeShouWu, RPMP) was widely used. In recent years, RPMP ethanol extract has been reported for the treatment of non-alcoholic fatty liver disease (NAFLD). However, the role of RPMP ethanol extract in the treatment of NAFLD has not been fully elucidated. Therefore, we examined the optimal therapeutic dose of RPMP ethanol extracts. Afterward, a mouse model of non-alcoholic fatty liver induced by a high-fat diet (HFD) was treated with RPMP ethanol extract to further evaluate the mechanism of action of RPMP ethanol extract treatment. And the serum lipid metabolism indexes and liver function indexes showed that the RPMP ethanol extract in the 1.35 g/kg dose group exhibited better therapeutic effects than the 2.70 g/kg dose group. Meanwhile, RPMP ethanol extract can regulate the biochemical indicators of serum and liver to normal levels, and effectively reduce liver steatosis and lipid deposition. RPMP ethanol extract treatment restored HFD-induced disruption of the compositional structure of the intestinal microbial (IM) and bile acids (BAs) pools. And restore the reduced expression of intestinal barrier-related genes caused by HFD administration, which also effectively regulates the expression of genes related to the metabolism of BAs in mice. Thus, RPMP ethanol extract can effectively improve the abnormal lipid metabolism and hepatic lipid accumulation caused by HFD, which may be related to the regulation of IM composition, maintenance of intestinal barrier function, and normal cholesterol metabolism in the body.
在用于脂质代谢的中药处方中，（制何首乌，RPMP）被广泛使用。近年来，已有报道称RPMP乙醇提取物可用于治疗非酒精性脂肪性肝病（NAFLD）。然而，RPMP乙醇提取物在治疗NAFLD中的作用尚未完全阐明。因此，我们研究了RPMP乙醇提取物的最佳治疗剂量。随后，用RPMP乙醇提取物处理高脂饮食（HFD）诱导的非酒精性脂肪肝小鼠模型，以进一步评估RPMP乙醇提取物治疗的作用机制。血清脂质代谢指标和肝功能指标显示，1.35 g/kg剂量组的RPMP乙醇提取物比2.70 g/kg剂量组表现出更好的治疗效果。同时，RPMP乙醇提取物可将血清和肝脏的生化指标调节至正常水平，并有效减轻肝脏脂肪变性和脂质沉积。RPMP乙醇提取物治疗恢复了HFD诱导的肠道微生物（IM）和胆汁酸（BAs）池组成结构的破坏。并恢复了HFD给药引起的肠道屏障相关基因表达降低，这也有效地调节了小鼠体内与BAs代谢相关基因的表达。因此，RPMP乙醇提取物可有效改善HFD引起的脂质代谢异常和肝脏脂质蓄积，这可能与调节IM组成、维持肠道屏障功能以及体内正常胆固醇代谢有关。
